• Post category:publication

7 April 2024 ISB 2001 Oral Presentation: ISB 2001, a BCMA and CD38 dual targeting T-cell engager, demonstrates superior cytotoxicity relative to teclistamab in the samples of patients relapsing from…

Continue ReadingPub3


  • Post category:publication

12 Dec 2022 ISB 1442 Poster: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose- Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma Jiang T.…

Continue ReadingPub2


  • Post category:publication

13 Apr 2022 ISB 1442 ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38+ Malignancies Sammicheli S. et al. American Association for…

Continue ReadingPub1